Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 276 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergic Rhinosinusitis Clear all
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

NCT03887026
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

NCT00638118
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
15 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

NCT01817790
View directory record Official record
Conditions
Allergic Rhinitis, Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
626 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Olfactory Dysfunction in Seasonal Allergic Rhinitis

NCT00361439
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 59 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults

NCT03814720
View directory record Official record
Conditions
Influenza Infection
Interventions
VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348
View directory record Official record
Conditions
Allergic Asthma, Atopic Dermatitis, Allergic Rhinitis, Healthy Volunteers
Interventions
Placebo, Omalizumab, MEDI4212 5 mg Subcutaneous, MEDI4212 15 mg Subcutaneous, MEDI4212 60 mg Subcutaneous, MEDI4212 150 mg Subcutaneous, MEDI4212 300 mg Subcutaneous, MEDI4212 300 mg Intravenous
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
295 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
7
States / cities
Cypress, California • Glendale, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Trial of Point of Care Information in Ambulatory Pediatrics

NCT00368823
View directory record Official record
Conditions
Acute Otitis Media, Allergic Rhinitis, Sinusitis, Constipation, Pharyngitis, Croup, Urticaria, Bronchiolitis
Interventions
Electronic point-of-care delivery system
Device
Lead sponsor
University of Washington
Other
Eligibility
0 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2003
U.S. locations
2
States / cities
Seattle, Washington • Skagit Valley, Washington
Source: ClinicalTrials.gov public record
Updated Aug 29, 2006 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

NCT00790023
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
80 mcg Ciclesonide, 160 mcg Ciclesonide, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 21, 2026, 10:58 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Doses of HA115 and Food Effect in Healthy Adult Volunteers

NCT03567694
View directory record Official record
Conditions
Asthma
Interventions
HA115, Placebo
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Study Of Patients With Allergic Rhinitis And Asthma

NCT00296530
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, montelukast
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
80
States / cities
Ozark, Alabama • Tempe, Arizona • Little Rock, Arkansas + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)

NCT00197262
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
18
States / cities
Chicago, Illinois • Indianapolis, Indiana • Lafayette, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Not applicable Interventional Results available

The Effect of Omalizumab on Responses to Cat Allergen Challenge

NCT00604786
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
omalizumab, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy

NCT02676765
View directory record Official record
Conditions
Immunologic Desensitization
Interventions
allergen extract tablet, Placebo tablet
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 21, 2026, 10:58 AM EDT
Enrolling by invitation Not applicable Interventional

A Randomized Controlled Trial Comparing Posterior Nasal Nerve Ablation Procedures for Chronic Rhinitis

NCT07706595
View directory record Official record
Conditions
Chronic Rhinitis, Non-allergic Rhinitis
Interventions
RhinAer, Neuromark, Clarifix
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)

NCT00346775
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate, Flunisolide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
7
States / cities
Fresno, California • Napa, California • Roseville, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

NCT00619801
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years to 6 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 21, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics

NCT04670627
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Rhinovirus
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Dupilumab in Allergic Fungal Rhinosinusitis (AFRS)

NCT04684524
View directory record Official record
Conditions
Allergic Fungal Rhinosinusitis
Interventions
Dupilumab SAR231893, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
11
States / cities
Tampa, Florida • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 10:58 AM EDT
Completed No phase listed Observational

Dietary Intake in Adults From the GA2LEN Folow-up Survey

NCT03251157
View directory record Official record
Conditions
Asthma, Lung Function Decreased, Food Allergy, Allergic Sensitisation, Allergic Rhinitis, COPD, Atopy
Interventions
Dietary intake of various nutrients, foods and biocompounds
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years to 75 Years
Enrollment
3,500 participants
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray

NCT01401465
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide, mometasone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
Huntington Beach, California • Mission Veijo, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 21, 2026, 10:58 AM EDT
Not listed Not applicable Interventional

Effect of Omalizumab (Xolair) in Treatment of Patients With AERD and Allergy Asthma

NCT00286416
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
omalizumab (Xolair)
Drug
Lead sponsor
Scripps Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced Oct 21, 2026, 10:58 AM EDT